Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Jun 03, 2019 Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
- May 01, 2019 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results